|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 123 JPY | 0.00% |
|
-3.15% | -8.89% |
| Apr. 01 | Chiome Bioscience Cancels License Agreements with ADC Therapeutics | MT |
| Feb. 13 | Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited | CI |
Chiome Bioscience Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was JPY 630.82 million compared to JPY 712.93 million a year ago. Net loss was JPY 1,242.87 million compared to JPY 1,479.9 million a year ago.
Basic loss per share from continuing operations was JPY 28.26 compared to JPY 36.74 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.89% | 43.53M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
CHIOME BIOSCIENCE INC. 
